Johnson & Johnson
Close on Nov 3, 2026Market cap $641.44BP/E 40.4Yield 1.93%
Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib) by Quarter
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. operational growth YoY (%) (%)
Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib): 47.9% in Q3 2026, down 51.8 pts from a year earlier.
Where the Q3 2026 figure comes from
“|| US | 201 | 136 | 47.9 | 47.9 | —”
Source: Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 47.9% | -51.8 pts | Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗ |
| Q2 2026 | Jun 28, 2026 | 36.8% | – | Form 8-K (a2026q2exhibit991.htm, filed 2026-07-15) ↗ |
| Q1 2026 | Mar 29, 2026 | 55.1% | -12.9 pts | Form 8-K (a2026q1exhibit991.htm, filed 2026-04-14) ↗ |
| Q4 2025 | Dec 28, 2025 | 45.6% | – | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| Q3 2025 | Sep 28, 2025 | 99.7% | – | Form 8-K (a2025q3exhibit991.htm, filed 2025-10-14) ↗ |
| Q1 2025 | Mar 30, 2025 | 68.0% | – | Form 8-K (a2025q1exhibit991.htm, filed 2025-04-15) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson RYBREVANT / LAZCLUZE (amivantamab / lazertinib) (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-rybrevant-us-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.
See a number that looks wrong?